AGGF1和HIF-1α及VEGF表达与食管鳞癌放疗预后相关性研究

目的 食管癌是一种常见的上消化道恶性肿瘤,放射治疗是食管癌的主要治疗方法之一.本研究旨在探讨食管鳞癌组织中AGGF1和HIF-1α及VEGF的表达,及其与食管鳞癌临床病理特征、放疗疗效及预后的相关性.方法 采用免疫组化SP法,检测新疆医科大学附属肿瘤医院胸腹放疗科2011-01-01-2015-01-01收治的79例食管鳞癌和20例正常食管组织中AGGF1、HIF-1α和VEGF的表达,结合临床病理特征和随访资料进行相关分析.结果 79例食管鳞癌中AGGF1(x2=18.975,P＜0.001)、HIF-1α(x2 =26.884,P＜0.001)和VEGF(x2=22.702,P＜0.001)的表达显著高于20例正常食管组织中的表达.食管鳞癌中AGGF1(x2=8.134,P=0.004)和VEGF(x2 =5.175,P=0.023)的表达与淋巴结转移密切相关;HIF-1α的表达与临床分期(x2=5.882,P=0.015)、淋巴结转移(x2=7.712,P=0.005)和浸润深度(x2 =5.538,P=0.019)密切相关.食管鳞癌中VEGF和HIF-1α的表达呈正相关,r=0.333,P=0.003;AGGF1和VEGF的表达呈正相关,r=0.790,P＜0.001.放疗近期疗效与HIF-1α的表达呈负相关,r=-0.246,P=0.029.AGGF1(P=0.170)和VEGF(P=0.229)阳性表达组OS短于阴性组;HIF-1α阳性表达组OS显著短于阴性组,P=0.013.Cox多因素回归分析显示,HIF-1α阳性表达(P=0.002)、浸润深度(P=0.005)和临床分期(P＜0.001)是食管鳞癌患者生存预后的独立因素.结论 AGGF1,HIF-1α及VEGF在食管鳞癌组织中高表达,并与食管鳞癌临床病理特征密切相关,三者高表达可能对食管鳞癌的放疗疗效和生存预后有影响,可为提高食管鳞癌的放疗效果和改善生存预后提供新的思路和方法.     

SGLT1在肝癌组织中的表达及意义

目的:比较钠葡萄糖共转运体SGLT1在肝癌组织和癌旁组织的表达,及SGLT1与肝癌TNM分级的相关性。方法:采用SP免疫组化技术,对79例肝癌患者组织芯片进行染色,统计学分析。结果:SGLT1在肝癌中阳性率高于癌旁组织,差异具有统计学意义(P<0.001),并且SGLT1在肝癌中表达程度与肝癌TNM分期具有相关性(P<0.001)。结论:SGLT1在肝癌中表达程度与肝癌TNM分期具有相关性,提示SGLT1在肝癌的发生和发展中有意义,通过对SGLT1介导的肿瘤依赖葡萄糖能量代谢的研究,为肝癌的发展机制研究提供新的理论基础。     

缺失基因DLC-1在原发性肝癌中的表达及意义

目的:探讨缺失基因DLC-1在原发性肝癌组织中的表达及与临床病理因素的关系。方法:采用免疫组化法研究60例肝癌中DLC-1的表达水平,观察评估DLC-1的阳性表达与肿瘤分级、淋巴结转移等临床病理因素的相关性。结果:60例原发性肝癌组织中,DLC-1高表达38例,癌旁组织高表达57例,两者差异有统计学意义（P<0.001)。肝癌分期越高,DLC-1 mRNA表达越低（P=0.008)。有淋巴结转移者DLC-1 mRNA表达也明显低于无转移者（P=0.012)。结论:缺失基因DLC-1与原发性肝癌的分期及侵袭转移能力密切相关,在肝癌发生、发展过程中起着重要的作用。     

SPARCL1在肝癌中的表达及其临床意义

目的 探讨SPARCL1表达与肝癌患者术后预后的关系.方法 收集154例肝癌患者的术后石蜡切片标本、临床病理资料及随访资料,采用免疫组化染色方法对石蜡切片组织中SPARCL1进行检测.结果 不同肝癌组织中SPARCL1的水平具有差异;SPARCL1表达下调与门脉癌栓、病理分化差、TNM分期晚和BCLC分期晚等恶性指标显著相关;SPARCL1表达下调的肝癌患者其中位生存时间显著缩短(40.6个月 vs118.7个月,P=0.002).结论 SPARCL1在肝癌中表达下调,提示肝癌患者的预后不良.     

hOGG1在原发性肝癌和肝硬化组织中的表达及意义

目的 通过检测DNA修复酶hOGG1在原发性肝癌(hepatoeellular carcinoma,HCC)及肝硬化组织中的表达,探讨hOGG1在HCC和肝硬化组织中的表达特点及其与临床病理因素的关系.方法 应用EnVision免疫组化法检测41例非HCC正常肝组织、99例HCC、51例HCC癌旁肝硬化组织中hOGG1表达情况.结果 在HCC组织中hOGG1在细胞核与细胞质中均可表达,其中hOGG1细胞核阳性分度在正常组、肝硬化组、HCC组之间依次增高(P<0.001).多因素分析显示hOGG1蛋白在细胞核表达与ALT有关(OR=1.022,P=0.041),hOGG1蛋白在细胞浆表达与总胆红素有关(OR=1.155,P=0.018).结论 在HCC发生过程中hOGG1蛋白在肝细胞核中的表达可能随着病程进展而增强,反映了从肝硬化到肝癌进程中肝细胞内氧化应激状态的改变.     

PRR11在肝癌中的表达及其与预后的关系

摘 要：［目的］ 研究肝癌组织中富含脯氨酸蛋白11(PRR11)表达与肝癌临床病理参数之间的关系,以及PRR11表达对肝癌患者预后的影响。［方法］ 通过构建含243例肝癌的组织芯片,用免疫组化方法检测PRR11蛋白在肝癌组织中的表达。［结果］ 243例肝癌组织标本中,PRR11高表达与性别、AFP水平、HBSAg、HBeAg水平有关。Kaplan-Meier 生存分析显示：PRR11高表达患者总生存期短于低表达患者(36.5个月vs 46.3个月,P=0.007) ,且病理分期(Ⅰ～Ⅱ vs Ⅲ～Ⅳ：60.7个月vs 19.5个月,P=0.001)、主瘤直径(≤5cm vs ＞5cm：55.9个月vs 19.5个月,P<0.001)、有无癌栓(无 vs 有：49.3个月 vs 22.7个月,P<0.001)、子灶数目(≤1个 vs ＞1个：50.0个月vs 22.5个月,P<0.001)与总生存期均显著相关。Cox风险回归模型分析显示PRR11表达是肝癌患者的独立预后因素（P=0.007)。［结论］ PRR11在部分肝癌组织中高表达,是肝癌患者独立的不良预后因素。     

Maspin BCSG1及c-erbB-2表达与乳腺癌预后的关系

目的:探讨Maspin、BCSG1、c-erbB-2蛋白在乳腺癌中的表达及其与预后的关系.方法:选取临床病理资料完整并随访5年以上的137例乳腺癌病例,采用SP免疫组织化学技术检测乳腺癌组织中的Maspin、BCSG1、c-erbB-2蛋白的表达情况,结合临床及病理形态学资料用COX模型分析Maspin、BCSG1、c-erbB-2表达对预后的影响.结果:Maspin、BCSG1、c-erbB-2蛋白在乳腺癌组织中的阳性表达率分别为48.9%,67.2%,27.7%三者与生存时间显著相关(P＜0.01).结论:Maspin、BCSG1、c-erbB-2蛋白在乳腺癌中的表达与患者的生存期密切相关,可作为预测乳腺癌预后的参考指标.     

WFDC1基因在肝癌中的表达及其诊断和预后价值

目的：研究WFDC1基因在肝癌组织和细胞中的表达变化,探讨其与肝癌临床病理指标及生存预后之间的关系,为肝癌的诊断以及预后判断提供参考依据。方法：采用qPCR法分别检测肝癌患者的肿瘤组织和癌旁组织、MC-LR诱导的人肝细胞L02恶性转化细胞和肝癌细胞株SMMC-7721、HepG2、Hep3B、Huh-7中WFDC1 mRNA的表达水平。基于TCGA数据库,分析WFDC1基因在肝癌患者肿瘤组织（331例）和癌旁组织（50例）中的表达及其与临床病理指标和生存预后的关系。结果：qPCR检测结果表明,与癌旁组织比较,WFDC1 mRNA在肝癌组织、MC-LR诱导的L02恶性转化细胞以及肝癌细胞中的表达均显著下调（P < 0.05）。TCGA数据库中WFDC1 mRNA表达分析也表明,肝癌组织的表达显著低于癌旁组织（P < 0.01）,且WFDC1 mRNA的表达下调与肿瘤分级和临床分期高度相关（P < 0.05）。Kaplan-Meier分析表明,WFDC1 mRNA高表达患者生存时间高于低表达患者（Log-rank=4.80,P < 0.05）。ROC曲线分析结果表明,WFDC1 mRNA是一个特异度和灵敏度较好的肝癌诊断指标（AUC=0.829）。结论：WFDC1基因可能是一个抑癌基因,检测该基因的表达水平对肝癌患者的诊断和预后判断具有参考价值。     

转录因子Sp1表达与肝癌临床病理特征及预后的关系

  目的  通过研究肝癌组织内转录因子Sp1的表达及其与肝癌患者临床病理特征及预后的关系,探讨转录因子Sp1作为肝癌预后预测指标的可行性。  方法  对98例根治性切除术的肝细胞肝癌肿瘤组织芯片进行免疫组化检测Sp1的表达情况,分析其与肝癌患者临床病理特征及预后之间的关系。  结果  免疫组化结果显示Sp1在肝癌组织中表达明显高于对应正常肝脏组织,在有微血管侵犯的患者中升高尤其明显。进一步分析显示Sp1表达与肝癌患者术后总体生存率呈负相关,而与肝癌患者术后复发率呈正相关。  结论  转录因子Sp1在肝癌中明显高表达,可作为肝癌患者预后的独立预测指标。      

RACGAP1在肝细胞肝癌中的表达及临床意义

目的:研究RACGAP1在肝细胞肝癌(LIHC)组织中的表达及临床意义。方法:利用免疫组化方法检测RACGAP1在LIHC组织和癌旁组织中的表达,分析RACGAP1在LIHC组织表达与临床病理特征的关系。利用UALCAN数据库分析RACGAP1 mRNA在LIHC中表达与临床病理特征的关系。GEPIA数据库分析RACGAP1在LIHC中表达与预后的关系。结果:LIHC组织中RACGAP1表达显著高于癌旁组织的表达(P<0.05);LIHC组织中RACGAP1表达与TNM分期、病理分级、肿瘤大小有关(P<0.05),与性别、年龄、淋巴结转移、是否肝硬化、AFP水平、肿瘤位置无关(P>0.05)。UALCAN数据库分析结果显示RACGAP1 mRNA表达与LIHC患者的临床分期、病理分级相关(P<0.05)。GEPIA数据库分析结果显示在LIHC中RACGAP1高表达的患者总生存率和无病生存率显著低于低表达的患者(P<0.05)。结论:RACGAP1在LIHC中呈现高表达,与LIHC的发生、发展和预后不良相关,可以作为LIHC诊断、预后判断和治疗靶点。     

长链非编码RNA CCAL在肝癌中的表达及其对预后的影响

目的:检测LncRNA-CCAL在肝细胞癌(HCC)中的表达水平,并分析其与肝癌患者临床病理因素及预后的关系.方法:运用RT-PCR技术检测37例肝癌新鲜组织中CCAL的表达水平;运用原位杂交技术(ISH)检测120例肝癌患者组织切片中CCAL的表达水平,并运用卡方检验、COX回归模型、Kaplan-Meier生存曲线分析CCAL表达水平与肝癌患者临床病理因素及预后的关系.结果:37例肝癌新鲜组织标本中29例高表达,且癌组织中平均表达水平明显高于癌旁组织;120例肝癌患者组织切片中85例高表达,其表达水平与肝癌TMN分期和是否转移相关,而且CCAL较高表达的患者预后也相对较差,总生存率明显低于CCAL低表达的患者.结论:CCAL在肝细胞癌中高表达,是肝癌患者预后的独立影响因子.     

Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma

Despite the substantial data supporting the oncogenic role of Ack1, the predictive value and biologic role of Ack1 in hepatocellular carcinoma (HCC) metastasis remains unknown. In this study, both correlations of Ack1 expression with prognosis of HCC, and the role of Ack1 in metastasis of HCC were investigated in vitro and in vivo. Our results showed that Ack1 was overexpressed in human HCC tissues and cell lines. High Ack1 expression was associated with HCC metastasis and determined as a significant and independent prognostic factor for HCC after liver resection. Ack1 promoted HCC invasion and metastasis in vitro and in vivo. Mechanistically, we confirmed that Ack1 enhanced invasion and metastasis of HCC via EMT by mediating AKT phosphorylation. In conclusion, our study shows Ack1 is a novel prognostic biomarker for HCC and promotes metastasis of HCC via EMT by activating AKT signaling.     

Cortactin overexpression correlates with poor prognosis in hepatocellular carcinoma

Objective: To investigate cortactin expression in hepatocellular carcinoma (HCC) and explore its significance in the prognosis of HCC patients.Methods: Immunohistochemistry was performed for paraffin samples of 119 pairs of HCC tissues (HCCs) and paratumorous liver tissues (PTLTs) to evaluate cortactin expression. The cortactin expression difference in HCCs and PTLTs were analyzed by the McNemar's test. The relationship of cortactin expressions in HCCs and clinicopathologic factors was analyzed with Mann-Whitney U test. The Kaplan-Meier method and log-rank test were employed to compare the overall survival between Cortactin negative expression group, weak expression group and strong expression group. Expression of cortactin was further determined in 19 pairs of fresh HCCs and PTLTs specimens with Western blotting.Results: Cortactin expression rate was significantly higher in HCCs (53/119, 44.5%) than that in PTLTs (2/119, 1.7%) (P<0.001). The upregulated cortactin expression in HCCs was significantly correlated to absence of capsule formation (P=0.012), vascular invasion (P=0.037) and high Edmondson-Steiner grade (P=0.020), and predicted shorter overall survival. Western blotting demonstrated that cortactin expression was upregulated in 9 out of 19 HCCs (47.4%) compared to corresponding PTLTs.Conclusion: Cortactin expression is upregulated in HCC and is related to shorter overall survival of patients, suggesting that cortactin might play roles in the metastasis of HCC and predict a poor prognosis of HCC patients.     

Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients

Little research has been done to test the usefulness of T-lymphoma invasion and metastasis 1 (Tiam1) as a prognostic marker for hepatocellular carcinoma (HCC). In this study, we investigated Tiam1 expression and its prognostic value for HCC. HCC surgical tissue samples were taken from 152 HCC patients who had been followed up for 5 years. Overexpression of Tiam1 (Tiam1 2+ to 3+) was shown in 63.8% of the cases. The Tiam1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the Tiam1 overexpression group had a significantly shorter overall survival time than the Tiam1 downexpression group (p=0.008). Multivariate analysis showed that Tiam1 expression was a significant and independent prognostic parameter (p=0.042) for HCC patients. Tiam1 expression may be a novel and independent predictor for the prognosis of HCC patients.     

Elevated expression of Cripto-1 correlates with poor prognosis in hepatocellular carcinoma

Cripto-1 could promote tumorigenesis in a wide range of carcinomas, yet little is known in hepatocellular carcinoma (HCC). The expression of Cripto-1 and MMP-9 were assessed by immunohistochemistry in 205 HCC specimens. The correlation between Cripto-1 and MMP-9, clinicopathological/prognostic value in HCC was examined. Cripto-1 overexpression was correlated with larger tumor, TNM stage, BCLC stage and tumor recurrence. In multivariate analyses, Cripto-1 was an independent predictor for overall survival (OS) and time to recurrence (TTR). Cripto-1 expression was increased in TNM and BCLC stage-dependent manner. Cripto-1 overexpression was associated with poor prognosis in patients subgroups stratified by tumor size, tumor differentiation, TNM and BCLC stage. In addition, Cripto-1 was positively correlated with MMP-9 among 205 HCC samples. Patients with Cripto-1 upregulation had poor OS and shorter TTR in low and high aggressiveness groups. Furthermore, Cripto-1 had predictive validity for early and late recurrence in HCC patients. Combination of Cripto-1 and serum AFP was correlated with OS and TTR. In conclusion, Cripto-1 overexpression contributes to aggressiveness and poor prognosis of HCC. Cripto-1/AFP expression could be a potential prognostic biomarker for survival in HCC patients.     

Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma

Objective

Regulatory factor X1 (RFX1) deletion has been reported to be correlated with poor prognosis of some types of cancer. The present study aimed to investigate the prognostic value of RFX1 in HCC, especially in small hepatocellular carcinoma.

Increased RBM12 expression predicts poor prognosis in hepatocellular carcinoma based on bioinformatics

BackgroundLiver cancer is one of the major causes of cancer death worldwide, incurring high mortality and a significant financial burden on the healthcare system. Abnormal RNA-binding proteins (RBPs) have been found to be associated with carcinogenesis in liver cancer. Among these, RNA-binding motif protein 12 (RBM12) is located in the exon junction complex (EJC). The goal of this study was to determine what role RBM12 plays in hepatocellular carcinoma (HCC) from a biological perspective.MethodsThe Tumor IMmune Estimation Resource (TIMER) and the Human Protein Atlas database were used to examine the expression level of RBM12, with the UALCAN and Gene Expression Profiling Interactive Analysis (GEPIA) databases used to investigate the relationship between RBM12 and other noteworthy clinical features. RBM12 expression in cells and tissue samples was detected using quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis. The functional network of RBM12 in HCC was studied using LinkedOmics and gene set enrichment analysis (GSEA), while the effects of hypomethylation on the expression of RBM12 in HCC was investigated using methylation databases. Finally, we used TIMER and CIBERSORT to investigate the relationship between immune cell infiltration and RBM12 in HCC.ResultsRBM12 is highly elevated in HCC tissues and cells, and it can be used to predict the prognosis of patients with HCC. Analysis with LinkedOmics and GSEA revealed RBM12 to be closely linked with tumor progression. Furthermore, hypomethylation was linked to an increase in RBM12 expression in HCC, while RBM12 was associated with immune cell infiltration.ConclusionsThis study shows that an elevated level of RBM12 in HCC indicates a poor patient prognosis. Furthermore, according to LinkedOmics and GSEA analyses, RBM12 was implicated in the most important hallmark pathways. Our findings suggest that RBM12 overexpression is caused by hypomethylation and that RBM12 plays a key role in liver cancer tumor immunity.